Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Polymorphisms of CYP2A6 and its practical consequences.

H Raunio1, A Rautio, H Gullstén

  • 1Department of Pharmacology and Toxicology, University of Kuopio, Box1627, 70211 Kuopio, Finland. hannu.raunio@uku.fi

British Journal of Clinical Pharmacology
|October 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Future directions for monitoring and human health research for the Arctic Monitoring and Assessment Programme.

Global health action·2018
Same author

Quantitative estimation of mercury intake by toxicokinetic modelling based on total mercury levels in humans.

Environment international·2018
Same author

The xenoestrogens, bisphenol A and para-nonylphenol, decrease the expression of the ABCG2 transporter protein in human term placental explant cultures.

Molecular and cellular endocrinology·2016
Same author

Is geographical distance a barrier in the use of public primary health services among rural and urban young adults? Experience from Northern Finland.

Public health·2015
Same author

Organic anion transporter 4 (OAT 4) modifies placental transfer of perfluorinated alkyl acids PFOS and PFOA in human placental ex vivo perfusion system.

Placenta·2015
Same author

Cadmium inhibits ABCG2 transporter function in BeWo choriocarcinoma cells and MCF-7 cells overexpressing ABCG2.

Placenta·2012

The CYP2A6 enzyme metabolizes nicotine. Genetic variations in CYP2A6 influence smoking habits and lung cancer risk, particularly in Asian populations, but associations are less clear in Caucasians.

Area of Science:

  • Pharmacogenomics
  • Enzyme kinetics
  • Molecular biology

Background:

  • Cytochrome P450 2A6 (CYP2A6) is a key hepatic enzyme.
  • CYP2A6 metabolizes nicotine and tobacco-specific nitrosamines.
  • Genetic variations in CYP2A6 influence xenobiotic metabolism.

Purpose of the Study:

  • To investigate the CYP2A6 gene cluster organization and polymorphic alleles.
  • To examine the relationship between CYP2A6 genetic status, smoking habits, and lung cancer risk.

Main Methods:

  • Characterization of the CYP2A6 gene cluster and its alleles.
  • Analysis of CYP2A6 gene deletions and point mutations.
  • Case-control studies on CYP2A6 polymorphism and smoking-related diseases.

Related Experiment Videos

Main Results:

  • Identified CYP2A6 alleles with deficient gene function, including point mutations and gene deletions.
  • Deletion alleles are most frequent in Oriental populations (up to 20%).
  • Japanese studies suggest CYP2A6 poor metabolizers have altered nicotine kinetics and potentially lower lung cancer risk.

Conclusions:

  • CYP2A6 genetic variations are population-specific and impact nicotine metabolism.
  • CYP2A6 polymorphism may influence lung cancer risk, particularly in Asian populations.
  • Associations between CYP2A6 variants and smoking-related risks are less evident in Caucasian populations.